Behçet's disease: A clinical review

Wounds

Volumn 14, Issue 8, 2002, Pages 275-283

  MacCormack, Mollie ^a   Phillips, Tania ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; AMINOTRANSFERASE; ANESTHETIC AGENT; AZATHIOPRINE; CHLORHEXIDINE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; GLYCEROL; LIDOCAINE; METHOTREXATE; STEROID; SUCRALFATE; TETRACYCLINE; THALIDOMIDE; TRIAMCINOLONE;

ALOPECIA; ANOREXIA; ARTHRITIS; BEHCET DISEASE; CARDIOVASCULAR SYSTEM; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; EYE DISEASE; EYE INFLAMMATION; GASTROINTESTINAL ABSORPTION; GENITAL ULCER; HUMAN; INFLAMMATORY DISEASE; LIVER TOXICITY; MOUTH ULCER; MUSCULOSKELETAL SYSTEM; NAUSEA; NERVOUS SYSTEM; NEUROPATHY; PREVALENCE; PYODERMA GANGRENOSUM; RESPIRATORY SYSTEM; REVIEW; SEDATION; SKIN DEFECT; SYSTEMIC DISEASE; TERATOGENICITY; VOMITING; WEIGHT REDUCTION;

EID: 0036810455     PISSN: 10447946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Behçet H. Ueber rezidiverende, aphtoese, durch ein virus veru sachte geschwuere am mund, am auge, und an den genitalien. Dermatol Wochendchr 1937;105:1152-7.
2. Feigenbaum A. Description of Behçet's syndrome in the Hippocratic third book of endemic disease. Brit J Ophthalmol 1956;40:355-7.
3. Verity DH, Marr JE, Ohno S, et al. Behçet's disease, the silk road and HLA-B51: Historical and geographical perspectives. Tissue Antigens 1999;54:213-20.
4. Adamantiades B. A case of recurrent hypopon iritis. Medical Society of Athens 1930:586-93.
5. Sakane T, Takeno M, Suzuki N, et al. Behçet's disease. New Eng J Med 1999;341:1284-91.
6. Tuzun Y, Yurdakul S, Mat C, et al. Epidemiology of Behçet's syndrome in Turkey. Int J Dermatol 1996;35:618-20.
7. Nakae K, Masaki F, Hashimoto T, et al. Recent epidemiological features of Behçet's disease in Japan. In: Wechsler B, Godeau P (eds). Behçet's Disease. Amsterdam: Excerpta Medica, 1993:145-51.
8. Kaklamani VG, Variopouls G, Kaklamanis PG. Behçet's disease. Semin Arthritis Rheum 1998;27:197-217.
9. Pickering M, Haskard DO. Behçet's syndrome. J Royal Col Phys London 2000;34:169-77.
10. Schreiner DT, Jorizzo JL. Behçet's disease and complex apthosis. Dermatol Clin 1987;5:760-78.
11. Ghate J, Jorizzo J. Behçet's disease and complex aphthosis. J Am Acad Dermatol 1999;40:1-18.
12. Davies PG, Fordham JN, Kirwan JR, et al. The pathergy test and Behçet's syndrome in Britain. Ann Rheum Dis 1984;43:70-3.
13. Munro CS, Cox NH. Pyoderma gangrenosum associated with Behçet's syndrome - Response to thalidomide. Clin Exp Dermatol 1998;13:408-10.
14. Rustin M, Gilkes J, Robinson T, et al. Pyoderma gangrenosum associated with Behçet's disease: Treatment with thalidomide. J Am Acad Dermatol 1990;23(5):941-4.
15. Chen K, Kawahara Y, Miyakawa S, et al. Cutaneous vasculitis in Behçet's disease: A clinical and histopathologic study of 20 patients. J Am Acad Dermatol 1997;36:689-96.
16. Önder M, Gürer MA. The multiple faces of Behçet's disease and its aetiological factors. J Euro Acad Dematol Vener 2001;15:126-36.
17. Jorizzo JL. Behçet's disease: An update based on the 1985 international conference in London. Arch Dermatol 1986;122:556-8.
18. Tohme A, Haddad F, Ghayad E. Neurologic manifestations in Behçet's disease: 16 Cases in a cohort of 110 patients. Ann Med Interne 1997;143:832-5.
19. Farah S, Al-Shubaili A, Montaser A, et al. Behçet's syndrome: A report of 41 patients with emphasis on neurological manifestations. J Neurol Neurosurg Psychiatry 1998;64:382-4.
20. Akman-Demir G, Baykan-Kurt B, Serdaroglu P, et al. Seven-year follow-up of neurologic involvement in Behçet syndrome. Arch Neuro 1996;53:691-4.
21. Golden BD, Goel A, Mitnick HJ. Behçet-type vasculopathy in a patient without the diagnostic features of Behçet's disease. Arthr Rheum 1996;39:1926-30.
22. Nesrin M, Burgess M, Bishop PW. Intracardiac thrombus in Behçet's disease: A systemic review. Chest 200;118:479-87.
23. Erkan, F, Gül A, Tasali E. Pulmonary manisfestations of Behçet's disease. Thorax 2001;56:572-8.
24. Benamour S, Zeroul B, Alaoui FZ. Joint manisfestations in Behçet's disease: A review of 340 cases. Rev Rheumatol Engl Ed 1998;65:299-307.
25. Bayraktar Y, Ozaslan E, Van Thiel DH. Gastrointestinal manifestations of Behçet's disease. J Clin Gastro 2000:30;144-54.
26. Balabanova M, Calamia K, Perniciaro C, et al. A study of the cutaneous manisfestations of Behçet's disease in patient's from the United States. J Am Acad Dermatol 1999;141:540-5.
27. International Study Group Criteria for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990;335:1078-80.
28. O'Duffy JD, Goldstein NP. Neurologic involvement in seven patients with Behçet's disease. Am J Med 1976;61:170-8.
29. Behçet's Disease Research Committee of Japan. Behçet's disease: Guide to diagnosis of Behçet's disease. Jpn J Opthalmol 1974;18:291-4.
30. Mason RM, Barnes CG. Behçet's syndrome with arthritis. Ann Rheum Dis 1969;28:95-103.
31. Dundar SV, Gencap U, Simsek H. Familial cases of Behçet's disease. Br J Dermatol 1985;113:319-21.
32. Zouboulis CC, Kötter I, Djawari D, et al. Epidemiological features of Adamantiades-Behçet's disease in Germany and Europe. Yonsei Med J 1997;38:411-22.
33. Mizuki N, Ohno S, Tanaka H, et al. Association of HLA-B51 and lack of association of class II alleles with Behçet's disease. Tissue Antigens 1992;40:22-30.
34. Chajek-Shaul T, Pisanty S, Knobler H, et al. HLA-B51 may serve as an immunogenetic marker for patients with Behçet's syndrome. Am J Med 1987;83:666-72.
35. Lee S, Koh YJ, Kim DH, et al. A study of HLA antigens in Behçet's syndrome. Yonsei Med J 1988;29:259-62.
36. Ohno S, Ohguchi M, Hirose S, et al. Close association of HLA-BW51 with Behçet's disease. Arch Ophthalmol 1982;100:1455-8.
37. Chang HK, Kim JU, Cheon KS, et al. HLA-B51 and its allelic types in association with Behçet's disease and recurrent aphthous stomatitis in Korea. Clin Exp Rheumatol 2001;19:S31-5.
38. Salvarani C, Boiardi L, Mantovani V, et al. Association of MICA alleles and HLA-B51 in Italian patients with Behçet's disease. J Rheumatol 2001;28:1867-70.
39. Nakae K, Masaki F, Hashimoto T, et al. Recent epidemiological features of Behçet's disease in Japan. In: Wechsler B, Godeau P (eds). Behçet's Disease. Amsterdam: Excerpta Medica, 1993:145-51.
40. Gul A, Uyar FA, Inanc M, et al. Lack of association of HLA-B*51 with a severe disease course in Behçet's disease. Rheumatology 2001;40:668-72.
41. Takeno M, Kariyone A, Yamashita N, et al. Excessive function of peripheral blood neutrophils from patients with Behçet's disease and form HLA-B51 transgenic mice. Arthrit Rheum 1995;38:426-33.
42. Mege JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte derived tumor necrosis alpha, interleukin-6, IL-8 and increased superoxide gerneration in Behçet's disease. A cooperative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993;20:1544-9.
43. Eksioglu-Demiralp E, Direskeneli H, Kibaroglu A, et al. Neutrophil activation in Behçet's disease. Clin Exp Rheumatol 2001;19:S19-24.
44. Tuzun B, Tuzun Y, Yurdakul S, et al. Neutrophil chemotaxis in Behçet's syndrome. Ann Rheum Dis 1999;58:658.
45. Farssanito MA, Dammacco R, Caffaorio P, et al. Th1 polarization of the immune response in Behçet's disease: A pututative role of IL-12. Arthritis Rheum 1999;42:1967-74.
46. Sugi-Ikai N, Nakazawa M, Nakamura S, et al. Increased frequencies of interleukin-2 and interferon gamma producing T cells in patients with active Behçet's disease. Invest Opthalmol Vis Sci 1998;39:996-1004.
47. Raziuddin S, al-Dalaan A, Bahabri S, et al. Divergent cytokine production profile in Behçet's disease. Altered Th1/Th2 cell cytokine pattern. J Rheumatol 1998;25:329-33.
48. Lee S, Bang D, Cho YH. Polymerase chain reaction reveals herpes simplex virus DNA in saliva of patients with Behçet's disease. Arch Dermatol Res 1996;288:179-83.
49. Mizushima Y, Matsuda T, Hoshi K, et al. Induction of Behçet's disease symptoms after dental treatment and streptococcal antigen skin test. J Rheumatol 1988;15:1029-30.
50. Münke H, Stockmann F, Ramadori G. Possible association between Behçet's syndrome and chronic Hepatitis C virus infection. N Engl J Med 1995;332:400-1.
51. Ilter N, Senol E, Gürer MA, et al. Behçet's disease and HCV infection. Int J Dermatol 2000;39:396-7.
52. Lehner T. The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behçet's disease. Intern Rev Immunol 1997;14:21-32.
53. Pervin K, Childerstone A, Shinnick T, et al. T cell epitope expression of mycobacterial and homologous human 65-kilodalton heat shock protein peptides in short term cell lines from patients with Behçet's disease. J Immunol 1993;151:2273-82.
54. Kaneko S, Suzuki N, Yamashita N, et al. Characteriztion of T cells specific for an epitope of human 60-kD heat shock protein in patients with Behçet's disease in Japan. Clin Exp Immunol 1997;108:204-12.
55. Weedon D. Skin Pathology. Edinborough: Harcourt Publishers Ltd, 1997.
56. Alpsoy E, Er H, Durusoy C, et al. The use of sulcrafate suspension in the treatment of oral and genital ulceration of Behçet's disease. Arch Dermatol 1999;135:529-32.
57. Sander HM, Randle HW. Use of colchicine in Behçet's syndrome. Cutis 1986;37:344-8.
58. Masuda K, Nakajima A, Urayama A, et al. Double masked trial of cyclosporin versus colchicine and long term open study of cyclosporin in Behçet's disease. Lancet 1989;1:1093-6.
59. Yurdakul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behçet's syndrome. Arthrit Rheum 2001;44:2686-9.
60. Convit J, Goihman-Yahr M, Rondon-Lugo AJ. Effectiveness of dapsone in Behçet's disease. Brit J Dermatol 1984;111:629-30.
61. Sharquie KE. Suppression of Behçet's disease with dapsone. Brit J Dermatol 1982;110:493-4.
62. Kaklamani VG, Kaklamanis PG. Treatment of Behçet's disease: An update. Seminars in Arthritis & Rheumatism 2001;30:299-31.
63. Barnes CG, Yazici H. Behçet's syndrome. Rheumatology 1999;38:1771-4.
64. Hirohata S, Suda H, Hashimoto T. Low-dose weekly methotrexate for progressive neuropsy-chiatric manifestations in Behçet's disease. J Neurological Sci 1998;159:181-5.
65. Jorizzo JL, White WL, Wise CM, et al. Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: Cutaneous polyarteritis nodosa and Behçet's disease. J Am Acad Dermatol 1991;24:973-8.
66. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 1990;322:281-5.
67. Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behçet's syndrome: Effects on long-term prognosis. Arthrit Rheum 1997;40:769-74.
68. Avci O, Gurler N, Gunes AT. Efficacy of cyclosporine on mucocutaneous manifestations of Behçet's disease. J Am Acad Dermatol 1997;36:796-7.
69. Ozzyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporine A versus pulsed cyclophosphamide in Behçet's syndrome: A single masked trial. Br J Opthahnol 1992;76:241-3.
70. Kotake S, Higashi K, Yoshikawa K, et al. Central nervous system symptoms in patients with Behçet's disease receiving cyclosporine therapy. Ophthalmology 1999;106:586-9.
71. Davatchi F, Shahram F, Chams H, et al. Pulse cyclophosphamide for ocular lesions of Behçet's disease: Double-blind crossover study. Arthrit Rheum 1999;42:S320.
72. Yazici H, Yurdakul S, Hamurydan V. Behçet's syndrome: How should we treat it? Clin Immunother 1995;3:102-7.
73. Hamza MH. Treatment of Behçet's disease with thalidomide. Clin Rheumatol 1986;5:365-71.
74. Jorizzo JL, Schmalstieg FC, Solomon AR, et al. Thalidomide effects in Behçet's syndrome and pustular vasculitis. Arch Intern Med 1986;146:878-81.
75. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of Behçet's syndrome: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:443-59.
76. Powell RJ, Gardner-Medwin JM. Guideline for the clinical use and dispensing of thalidomide. Postgrad Med J 1994;70:901-4.
77. Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behçet's disease: A randomized placebo-controlled and double-blind study. Arch Dermatol 2002;138:467-71.
78. Zouboulis CC, Orfanos CE. Treatment of Adamantiades-Behçet's disease with systemic interferon alfa. Arch Dermatol 1998;134:1010-6.
79. Tsambaos D, Eichenberg D, Goos M. Behçet's syndrome: Treatment with recombinant leucocyte alfa-interferon. Arch Dermatol Res 1986;278:335-6.
80. Alpsoy E, Yilmaz E, Basaran E. Interferon theracyte for Behçet's disease. J Am Acad Dermatol 1994;31:617-9.
81. Boyvat A, Sisman-Solak C, Gurler A. Long-term effects of interferon alpha 2a treatment in Behçet's disease. Dermatology 2000;201:40-3.
82. Georgiou S, Monastirli A, Pasmatzi E, et al. Efficacy and safety of systemic recombinant interferon-alpha in Behçet's disease. J Int Med 1998;243:367-72.
83. Hamuryudan V, Yurdakul S, Rosenkaimer F, et al. Inefficacy of topical alpha interferon in the treatment of oral ulcers of Behçet's syndrome: A randomized, double-blind trial. Brit J Rheumatol 1991;30:395-6.